DrugPatentWatch Database Preview

Smithkline Beecham Company Profile

« Back to Dashboard

What is the competitive landscape for SMITHKLINE BEECHAM, and when can generic versions of SMITHKLINE BEECHAM drugs launch?

SMITHKLINE BEECHAM has six approved drugs.

There are two US patents protecting SMITHKLINE BEECHAM drugs.

There are fifty-one patent family members on SMITHKLINE BEECHAM drugs in seventeen countries.

Summary for Smithkline Beecham

International Patents:	51
US Patents:	2
Tradenames:	6
Ingredients:	6
NDAs:	6
Drug Master File Entries:	2
Patent Litigation for Smithkline Beecham:	See patent lawsuits for Smithkline Beecham

Drugs and US Patents for Smithkline Beecham

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Smithkline Beecham	RELAFEN	nabumetone	TABLET;ORAL	019583-002	Dec 24, 1991		DISCN	Yes	No
Smithkline Beecham	DYNACIRC	isradipine	CAPSULE;ORAL	019546-002	Dec 20, 1990		DISCN	Yes	No
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988		DISCN	No	No
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-001	Oct 20, 2006	AB	RX	Yes	No	7,268,156*PED				Y
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-001	Sep 14, 1995	AB	RX	Yes	No
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-004	May 29, 1997	AB	RX	Yes	No

Expired US Patents for Smithkline Beecham

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988	4,375,547
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-004	Oct 20, 2006	RE40000*PED
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-003	Oct 20, 2006	5,760,069*PED
Smithkline Beecham	COREG CR	carvedilol phosphate	CAPSULE, EXTENDED RELEASE;ORAL	022012-002	Oct 20, 2006	5,760,069*PED
Smithkline Beecham	COREG	carvedilol	TABLET;ORAL	020297-002	Sep 14, 1995	4,503,067*PED
Smithkline Beecham	RELAFEN	nabumetone	TABLET;ORAL	019583-001	Dec 24, 1991	4,420,639*PED

Paragraph IV (Patent) Challenges for SMITHKLINE BEECHAM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	40 mg		2007-12-21
	Oral Solution	15 mg/mL		2008-05-14
	Extended-release Capsules	10 mg and 20 mg		2008-03-18
	Extended-release Capsules	80 mg		2007-11-19
	Capsules	1 g		2008-11-10

International Patents for Smithkline Beecham Drugs

Country	Patent Number	Estimated Expiration
Japan	2005533823
Norway	20050427
China	1678305
Japan	5422545
Japan	4718116
South Korea	20040073433

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Smith And Nephew
• Smithkline Beecham